日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Increase of nitrous oxide-induced neurological disorders - a German multicenter experience

德国多中心研究发现,一氧化二氮诱发的神经系统疾病有所增加。

Meißner, Julius Nicolai; Neuneier, Janina; Bartzokis, Iason; Rehm, Mathias; Al-Hayali, Ahmad; Müller, Marcus; Paus, Sebastian; Limmroth, Volker; Fink, Gereon R; Petzold, Gabor C; Nitsch, Louisa

Prehospital Levetiracetam Use in Adults With Status Epilepticus: Results of a Multicenter Registry

院前使用左乙拉西坦治疗成人癫痫持续状态:一项多中心注册研究的结果

Burghaus, Lothar; Madlener, Marie; Kohle, Felix; Bruno, Emanuel F; Limmroth, Volker; Fink, Gereon R; Malter, Michael P

Communication, Coordination, and Security for People with Multiple Sclerosis (COCOS-MS): a randomised phase II clinical trial protocol

多发性硬化症患者的沟通、协调和安全(COCOS-MS):一项随机 II 期临床试验方案

Golla, Heidrun; Dillen, Kim; Hellmich, Martin; Dojan, Thomas; Ungeheuer, Solveig; Schmalz, Petra; Staß, Angelika; Mildenberger, Vanessa; Goereci, Yasemin; Dunkl, Veronika; Strupp, Julia; Fink, Gereon R; Voltz, Raymond; Stock, Stephanie; Cornely, Oliver; Stahmann, Alexander; Müller, Anne; Löcherbach, Peter; Burghaus, Lothar; Limmroth, Volker; Bonmann, Eckhard; Gerbershagen, Kathrin; Nelles, Gereon; Joist, Thomas; Haas, Judith; Temmes, Herbert; Warnke, Clemens

Ascertaining Medication Use and Patient-Reported Outcomes via an App and Exploring Gamification in Patients With Multiple Sclerosis Treated With Interferon β-1b: Observational Study

通过应用程序确定药物使用情况和患者报告结局,并探索游戏化在接受干扰素β-1b治疗的多发性硬化症患者中的应用:观察性研究

Limmroth, Volker; Bayer-Gersmann, Kirsten; Mueller, Christian; Schürks, Markus

Correction: Ascertaining Medication Use and Patient-Reported Outcomes via an App and Exploring Gamification in Patients With Multiple Sclerosis Treated With Interferon β-1b: Observational Study

更正:通过应用程序确定药物使用情况和患者报告结局,并探索游戏化在接受干扰素β-1b治疗的多发性硬化症患者中的应用:观察性研究

Limmroth, Volker; Bayer-Gersmann, Kirsten; Mueller, Christian; Schürks, Markus

Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)

多发性硬化症治疗共识小组(MSTCG):关于多发性硬化症疾病修饰疗法的立场声明(白皮书)

Wiendl, Heinz; Gold, Ralf; Berger, Thomas; Derfuss, Tobias; Linker, Ralf; Mäurer, Mathias; Aktas, Orhan; Baum, Karl; Berghoff, Martin; Bittner, Stefan; Chan, Andrew; Czaplinski, Adam; Deisenhammer, Florian; Di Pauli, Franziska; Du Pasquier, Renaud; Enzinger, Christian; Fertl, Elisabeth; Gass, Achim; Gehring, Klaus; Gobbi, Claudio; Goebels, Norbert; Guger, Michael; Haghikia, Aiden; Hartung, Hans-Peter; Heidenreich, Fedor; Hoffmann, Olaf; Kallmann, Boris; Kleinschnitz, Christoph; Klotz, Luisa; Leussink, Verena I; Leutmezer, Fritz; Limmroth, Volker; Lünemann, Jan D; Lutterotti, Andreas; Meuth, Sven G; Meyding-Lamadé, Uta; Platten, Michael; Rieckmann, Peter; Schmidt, Stephan; Tumani, Hayrettin; Weber, Frank; Weber, Martin S; Zettl, Uwe K; Ziemssen, Tjalf; Zipp, Frauke

[Multiple sclerosis treatment consensus group (MSTCG): position paper on disease-modifying treatment of multiple sclerosis 2021 (white paper)]

[多发性硬化症治疗共识小组(MSTCG):2021年多发性硬化症疾病修饰治疗立场文件(白皮书)]

Wiendl, Heinz; Gold, Ralf; Berger, Thomas; Derfuss, Tobias; Linker, Ralf; Mäurer, Mathias; Stangel, Martin; Aktas, Orhan; Baum, Karl; Berghoff, Martin; Bittner, Stefan; Chan, Andrew; Czaplinski, Adam; Deisenhammer, Florian; Di Pauli, Franziska; Du Pasquier, Renaud; Enzinger, Christian; Fertl, Elisabeth; Gass, Achim; Gehring, Klaus; Gobbi, Claudio; Goebels, Norbert; Guger, Michael; Haghikia, Aiden; Hartung, Hans-Peter; Heidenreich, Fedor; Hoffmann, Olaf; Hunter, Zoë R; Kallmann, Boris; Kleinschnitz, Christoph; Klotz, Luisa; Leussink, Verena; Leutmezer, Fritz; Limmroth, Volker; Lünemann, Jan D; Lutterotti, Andreas; Meuth, Sven G; Meyding-Lamadé, Uta; Platten, Michael; Rieckmann, Peter; Schmidt, Stephan; Tumani, Hayrettin; Weber, Martin S; Weber, Frank; Zettl, Uwe K; Ziemssen, Tjalf; Zipp, Frauke

Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study

在TOPAZ扩展研究中,对CARE-MS I和II期患者进行9年随访,评估阿仑单抗治疗高活动性疾病患者的疗效和安全性:事后分析

Ziemssen, Tjalf; Bass, Ann D; Berkovich, Regina; Comi, Giancarlo; Eichau, Sara; Hobart, Jeremy; Hunter, Samuel F; LaGanke, Christopher; Limmroth, Volker; Pelletier, Daniel; Pozzilli, Carlo; Schippling, Sven; Sousa, Livia; Traboulsee, Anthony; Uitdehaag, Bernard M J; Van Wijmeersch, Bart; Choudhry, Zia; Daizadeh, Nadia; Singer, Barry A

Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies

阿仑单抗治疗复发缓解型多发性硬化症患者的疗效:CARE-MS、扩展研究和TOPAZ研究的汇总分析

Comi, Giancarlo; Alroughani, Raed; Boster, Aaron L; Bass, Ann D; Berkovich, Regina; Fernández, Óscar; Kim, Ho Jin; Limmroth, Volker; Lycke, Jan; Macdonell, Richard Al; Sharrack, Basil; Singer, Barry A; Vermersch, Patrick; Wiendl, Heinz; Ziemssen, Tjalf; Jacobs, Alan; Daizadeh, Nadia; Rodriguez, Claudio E; Traboulsee, Anthony

Ifosfamide, Carboplatin, and Etoposide (ICE) in Combination with Regional Hyperthermia as Salvage Therapy in Patients with Locally Advanced Nonmetastatic and Metastatic Soft-Tissue Sarcoma

异环磷酰胺、卡铂和依托泊苷(ICE)联合区域性热疗作为局部晚期非转移性和转移性软组织肉瘤患者的挽救治疗

Bücklein, Veit; Limmroth, Christina; Kampmann, Eric; Schuebbe, Gesa; Issels, Rolf; Roeder, Falk; Angele, Martin; Dürr, Hans Roland; Knösel, Thomas; Abdel-Rahman, Sultan; Di Gioia, Dorit; Lindner, Lars H